LY-2584702 (tosylate salt)

LY-2584702 tosylate salt is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.

Product Specifications

CAS Number

[1082949-68-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Ribosomal S6 Kinase (RSK)

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/LY-2584702-tosylate-salt.html

Purity

99.50

Solubility

DMSO : 10.25 mg/mL (ultrasonic; warming)

Smiles

CN1C=C(C2=CC=C(F)C(C(F)(F)F)=C2)N=C1C3CCN(C4=C5C(NN=C5)=NC=N4)CC3.O=S(C6=CC=C(C)C=C6)(O)=O

Molecular Formula

C28H27F4N7O3S

Molecular Weight

617.62

Precautions

H302, H315, H319, H335

References & Citations

[1]Tolcher A, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumors. Eur J Cancer. 2014 Mar;50 (5) :867-75.|[2]Phung TL, et al. Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth. Cancer Res. 2015 Jan 1;75 (1) :40-50.|[3]Chen B, et al. Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients. PLoS One. 2017 Aug 9;12 (8) :e0182891.